Novel biological strategies in inflammatory bowel diseases

Inflammatory Bowel Diseases

Volumn 10, Issue 7 SUPPL. 1, 2004, Pages

  Vermeire, Severine ^a   Rutgeerts, Paul ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALICAFORSEN; ALPHA4 INTEGRIN; AZATHIOPRINE; BETA1A INTERFERON; CELL ADHESION MOLECULE; CORTISONE; CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; MERCAPTOPURINE; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; MLN 02; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; ONERCEPT; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 11; SEMAPIMOD; TACROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; VISILIZUMAB;

ARTICLE; CLINICAL TRIAL; COLITIS; COUGHING; CREATININE BLOOD LEVEL; CROHN DISEASE; DRUG ABSORPTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; ENTERITIS; ENZYME ACTIVITY; ENZYME INHIBITION; FLU LIKE SYNDROME; HUMAN; HYPERKALEMIA; HYPERTENSION; METABOLIC DISORDER; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKIN MANIFESTATION; STATISTICAL SIGNIFICANCE; TERATOGENESIS; TERATOGENICITY; TREMOR; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 1542410506     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200402001-00010     Document Type: Article

References (70)

1. Podolsky DK. Inflammatory Bowel Disease. N Engl J Med. 2002;347: 417-429.
2. Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. N Engl J Med. 1997;337:1029-1035.
3. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398-1405.
4. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and Safety of Retreatment With Anti-Tumor Necrosis Factor Antibody (Infliximab) to Maintain Remission in Crohn's Disease. Gastroenterology. 1999;117:761-769.
5. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359: 1541-1549.
6. D'haens G. Van Deventer S, Van Hogezand R et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology. 1999; 116:1029-1034.
7. Ricart E, Panaccione R, Loftus EV et al. Successful management of Crohn's disease of the ileoanal pouch with infliximab. Gastroenterology. 1999 Aug; 117(2):429-432.
8. Colombel JF, Ricart E, Loftus Jr. EV et al. Management of Crohn's disease (CD) of the ileoanal pouch with infliximab, Gastroenterol Suppl. 2003; T1364 Abstract
9. Parsi MA, Achkar JP, Richardson S, et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology. 2002;123: 707-713.
10. Vermeire S, Louis E, Carbonez A, et al. Logistic regression of clinical parameters influencing response to infliximab. Am J Gastroenterol. 2002; 97:2357-2363.
11. Taylor KD, Plevy SE, Yang H, et al. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology. 2001;120:1347-1355.
12. Esters N, Vermeire S, Joossens S, et al. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. Am J Gastroenterol. 2002;97:1458-1462.
13. Vermeire S, Louis E, Rutgeerts P, et al. The Nod2 gene does not influence response to infliximab in Crohn's disease. Gastroenterology. 2002;123: 106-111.
14. Mascheretti S, Hampe J, Croucher PJ, et al. Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials. Pharmacogenetics. 2002;12:509-515.
15. Louis E, Vermeire S, Rutgeerts P, et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol. 2002;37:818-824.
16. Su C, Salzberg BA, Lewis JD, et al. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol. 2002;97: 2577-2584.
17. Kohn A, Prantera C, Pera A, et al. Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients. Dig Liver Dis. 2002;34:626-630.
18. Kaser A, Mairinger T, Vogel W, et al. Infliximab in severe steroid-refractory ulcerative colitis: a pilot study. Wien Klin Wochenschr. 2001; 113:930-933.
19. Chey WY, Hussain A, Ryan C, et al. Infliximab for refractory ulcerative colitis. Am J Gastroenterol. 2001;96:2373-2381.
20. Gornet JM, Couve S, Hassani Z et al. Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study. Aliment Pharmacol Ther. 2003 15;18:175-181
21. Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2001;7:83-88.
22. Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut. 2003;52:998-1002.
23. Stack WA, Mann SD, Roy AJ, et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet. 1997;349:521-524.
24. Sandborn WJ, Feagan BG, Hanauer SB, et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology. 2001;120:1330-1338.
25. Sandborn WJ, Feagan B, Radford-Smith G et al. A randomised placebo-controlled trial of CDP571, a humanized monoclonal antibody to TNF-A in patients with moderate to severe Crohn's disease. Gastroenterol Suppl. 2003; A469 Abstract
26. Hanauer S, Present D, Targan SR et al. CDP571, a humanized monoclonal antibody to TNF-A, a well tolerated alternative in Crohn's disease patients who have experienced hypersensitivity reactions to infliximab. Gastroenterol Suppl. 2003; T1357 Abstract
27. Evans RC, Clarke L, Heath P, et al. Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571. Aliment Pharmacol Ther. 1997;11:1031-1035.
28. Sampaio EP, Sarno EN, Galilly R, et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med. 1991;173:699-703.
29. Bauditz J, Wedel S, Lochs H. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut. 2002;50:196-200.
30. Waters MF, Laing AB, Ambikapathy A, et al. Treatment of ulcerative colitis with thalidomide. Br Med J. 1979;1:792.
31. Ehrenpreis ED, Kane SV, Cohen LB, et al. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology. 1999;117:1271-1277.
32. Vasiliauskas EA, Kam LY, Abreu-Martin MT, et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology. 1999;117:1278-1287.
33. Sabate JM, Villarejo J, Lemann M, et al. An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease. Aliment Pharmacol Ther. 2002;16:1117-1124.
34. Hommes D, van den Blink B, Plasse T, et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology. 2002;122:7-14.
35. Plevy SE, Salzberg BA, Regueiro M et al. A humanized anti-CD3 monoclonal antibody, Visilizumab, for treatment of severe steroid-refractor ulcerative colitis: preliminary results of a phase I study. Gastroenterol Suppl. 2003; A62 Abstract
36. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001;121:1088-1094.
37. ten Hove T, van Montfrans C, Peppelenbosch MP, et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut. 2002;50:206-211.
38. Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology. 2003;124:1774-1785.
39. Rutgeerts P, Lemmens L, Van Assche G, et al. Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment Pharmacol Ther. 2003;17:185-192.
40. Vermeire S, Noman M, Van Assche G, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology. 2003;125:32-39.
41. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003; 348:601-608.
42. Fedorak RN, Gangl A, Elson CO, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology. 2000;119:1473-1482.
43. Schreiber S, Fedorak RN, Nielsen OH, et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology. 2000;119:1461-1472.
44. van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology. 1997;113:383-389.
45. Tilg H, van Montfrans C, van den Ende A, et al. Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut. 2002;50:191-195.
46. Colombel JF, Rutgeerts P, Malchow H, et al. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut. 2001; 49:42-46.
47. Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science. 2000;289:1352-1355.
48. Lindsay JO, Ciesielski CJ, Scheinin T, et al. The prevention and treatment of murine colitis using gene therapy with adenoviral vectors encoding IL-10. J Immunol. 2001;166:7625-7633.
49. Van Montfrans C, Rodriguez Pena MS. Pronk I et al. Prevention of colitis by interleukin 10-transduced T lymphocytes in the SCID mice transfer model. Gastroenterology. 2002;123:1865-1876.
50. Sands BE. Bank S, Sninsky CA et al. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology. 1999;117:58-64.
51. Sands BE, Winston BD, Salzberg B, et al. Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. Aliment Pharmacol Ther. 2002;16:399-406.
52. Nikolaus S, Rutgeerts P, Fedorak R, et al. Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut. 2003;52:1286-1290.
53. Burns RC, Rivera-Nieves J, Moskaluk CA, et al. Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn's disease in mice. Gastroenterology. 2001;121:1428-1436.
54. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology. 1998;114:1133-1142.
55. Schreiber S, Nikolaus S, Malchow H, et al. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology. 2001;120:1339-1346.
56. Yacyshyn BR, Chey WY, Goff J, et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut. 2002;51:30-36.
57. Gordon FH, Lai CW, Hamilton MI, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology. 2001;121:268-274.
58. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med. 2003;348:24-32.
59. Gordon FH, Hamilton MI, Donoghue S, et al. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther. 2002;16:699-705.
60. Feagan BG, Greenberg G, Wild G et al. Efficacy and safety of a humanized A4B7 antibody in active Crohn's disease (CD) Gastroenterol Suppl. 2003; A178 Abstract 178
61. Feagan BG, McDonald JWD, Greenberg G, et al. An ascending dose trial of a humanized A4B7 antibody in ulcerative colitis. Gastroenterology. 2000;118:A874. (abstract)
62. Baumgart DC, Wiedenmann B, Dignass AU. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment Pharmacol Ther. 2003;17:1273-1281.
63. Fellermann K, Tanko Z, Herrlinger KR, et al. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis. 2002; 8:317-324.
64. Lowry PW, Weaver AL, Tremaine WJ, et al. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae. Inflamm Bowel Dis. 1999;5:239-245.
65. Sandborn WJ. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. Am J Gastroenterol. 1997;92:876-879.
66. Skelly MM, Logan RE, Jenkins D, et al. Toxicity of mycophenolate mofetil in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2002;8:93-97.
67. Ford AC, Towler RJ, Moayyedi P, et al. Mycophenolate mofetil in refractory inflammatory bowel disease. Aliment Pharmacol Ther. 2003;17: 1365-1369.
68. Hassard PV, Vasiliauskas EA, Kam LY, et al. Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn's disease. Inflamm Bowel Dis. 2000;6:16-20.
69. Fellermann K, Steffen M, Stein J, et al. Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. Aliment Pharmacol Ther. 2000;14:171-176.
70. Neurath MF, Wanitschke R, Peters M, et al. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gut. 1999;44:625-628.